4.7 Article

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Journal

KIDNEY INTERNATIONAL
Volume 93, Issue 3, Pages 545-559

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2017.11.007

Keywords

antiretroviral therapy; APOL1; CKD progression; HIV; immune complex kidney disease; podocytopathy; renal pathology

Funding

  1. KDIGO
  2. National Institute on Drug Abuse
  3. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  4. NIH/NIDDK
  5. Gilead Sciences
  6. Merck Sharp Dohme
  7. ViiV Healthcare
  8. Adcock Ingram
  9. Medical Research Council of South Africa
  10. Akebia
  11. Amgen
  12. Bio Nano Consulting
  13. Boehringer Ingelheim
  14. Bristol Myers Squibb
  15. GlaxoSmithKline
  16. Janssen
  17. Otsuka
  18. UCB Celltech
  19. Vifor Fresenius Medical Care Renal Pharma
  20. Australian National Health & Medical Research Council
  21. British Heart Foundation
  22. Healthcare Quality Improvement Partnership
  23. Kidney Research UK
  24. National Institute for Health Research
  25. AMAG Pharmaceuticals
  26. AstraZeneca
  27. Bayer
  28. Daiichi Sankyo
  29. Medtronic
  30. Relypsa

Ask authors/readers for more resources

HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available